A multicentre, multinational study headed up by
rheumatologist Daniel Aletaha of MedUni Vienna as principal investigator has now shown that a new drug (sirukumab) is a very promising treatment option for these «refractory» patients.
«Opioids are not as safe as people had hoped,» says the lead author of the study,
Daniel H. Solomon, MD, a
rheumatologist and epidemiologist at Brigham and Women's Hospital, in Boston.